SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-21-003883
Filing Date
2021-11-10
Accepted
2021-11-10 06:37:35
Documents
14
Period of Report
2021-11-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cere-20211110.htm   iXBRL 8-K 53591
2 EX-99.1 cere-ex99_1.htm EX-99.1 282387
3 GRAPHIC img106327088_0.jpg GRAPHIC 9034
  Complete submission text file 0000950170-21-003883.txt   489461

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cere-20211110_lab.xml EX-101.LAB 14564
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cere-20211110.xsd EX-101.SCH 2484
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cere-20211110_pre.xml EX-101.PRE 10675
7 EXTRACTED XBRL INSTANCE DOCUMENT cere-20211110_htm.xml XML 5126
Mailing Address 222 JACOBS STREET SUITE 200 CAMBRIDGE MA 02141
Business Address 222 JACOBS STREET SUITE 200 CAMBRIDGE MA 02141 844-304-2048
Cerevel Therapeutics Holdings, Inc. (Filer) CIK: 0001805387 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39311 | Film No.: 211394303
SIC: 2834 Pharmaceutical Preparations